• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

The First Biomarker-Driven Treatment Trial for ME/CFS

SWAlexander

SWAlexander

Senior Member
Messages
1,945

Subsets Mean Success​

Until now, the heterogeneity of the patient population and the lack of a reliable biomarker to diagnose and prognose ME/CFS has thwarted clinical trials for both non-approved FDA drugs as well as repurposed agents.
We have recently identified elevated levels of inactive ATG-13 as a testable and targetable pathway for treating symptoms of post-exertional malaise.

Biomarker to Treatment Trial​

Rapamycin therapy inhibits mTOR and reduces autophagy disruption. We believe that a subset of patients may have chronic mTOR activation that can lead to the symptoms of ME/CFS. By taking rapamycin, the mTOR inhibitor, we hope that these people may see a significant reduction in symptoms.
We will track symptoms and autophagy markers in this study.
https://www.simmaronresearch.com/rapamycin-trial

What is: Chronic activation of the mTOR pathway has significant implications for cellular and organismal health
Short introduction: https://swaresearch.blogspot.com/2023/11/chronic-activation-of-mtor-pathway-has.html
 
You must log in or register to reply here.